304.96

1.87% -5.81

Pre-market: 304.39 -0.57 -0.19%

Charles River Laboratories International Inc (CRL)

Overview News Price History Option Chain Financials Discussions Forecast

Charles River Laboratories International Inc stock is traded at $304.96, with a volume of 1.92M. It is down -1.87% in the last 24 hours and up +5.71% over the past month. Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Previous Close:

$310.77

Open:

$319.8

24h Volume:

1.92M

Relative Volume:

2.10

Market Cap:

$14.56B

Revenue:

$4.03B

Net Income/Loss:

$-182.84M

P/E Ratio:

-81.10

EPS:

-3.7603

Net Cash Flow:

$391.29M

1W Performance:

+3.04%

1M Performance:

+5.71%

6M Performance:

+81.29%

1Y Performance:

+74.31%

1-Day Range:

$300.01

$333.30

1-Week Range:

$284.61

$333.30

52-Week Range:

$146.19

$333.30

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name

Charles River Laboratories International Inc

Sector

Healthcare (1066)

Industry

Diagnostics & Research (50)

Phone

781-222-6000

Address

251 BALLARDVALE ST, WILMINGTON, MA

Employee

19,700

Twitter

@criverlabs

Next Earnings Date

2026-11-04

Latest SEC Filings

CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, NTRA, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRL Charles River Laboratories International Inc	304.96	13.98B	4.03B	-182.84M	391.29M	-3.7603
TMO Thermo Fisher Scientific Inc	656.58	241.26B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	215.61	150.48B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	400.65	59.47B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	169.33	48.71B	7.23B	1.41B	1.09B	4.979
WAT Waters Corp	436.43	42.59B	3.77B	449.25M	240.68M	7.8556

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-17-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight
May-29-26	Upgrade	CLSA	Hold → Outperform
Apr-14-26	Initiated	RBC Capital Mkts	Outperform
Dec-15-25	Upgrade	BofA Securities	Neutral → Buy
Nov-17-25	Upgrade	Argus	Hold → Buy
Nov-06-25	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-06-25	Upgrade	William Blair	Mkt Perform → Outperform
Oct-02-25	Upgrade	Barclays	Equal Weight → Overweight
Sep-09-25	Upgrade	Jefferies	Hold → Buy
Jul-09-25	Upgrade	Citigroup	Neutral → Buy
May-23-25	Upgrade	Redburn Atlantic	Neutral → Buy
May-14-25	Upgrade	TD Cowen	Hold → Buy
May-08-25	Upgrade	Evercore ISI	In-line → Outperform
Mar-21-25	Downgrade	Goldman	Buy → Neutral
Mar-04-25	Upgrade	Citigroup	Sell → Neutral
Mar-03-25	Upgrade	Redburn Atlantic	Sell → Neutral
Jan-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Jan-17-25	Downgrade	UBS	Buy → Neutral
Nov-18-24	Downgrade	CLSA	Hold → Underperform
Nov-07-24	Upgrade	CLSA	Underperform → Hold
Oct-23-24	Initiated	CLSA	Underperform
Oct-14-24	Initiated	Redburn Atlantic	Sell
Oct-07-24	Downgrade	Evercore ISI	Outperform → In-line
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral
Oct-01-24	Downgrade	Citigroup	Neutral → Sell
Aug-08-24	Downgrade	JP Morgan	Overweight → Neutral
Aug-08-24	Downgrade	Robert W. Baird	Outperform → Neutral
Jun-28-24	Downgrade	Argus	Buy → Hold
Jun-07-24	Initiated	Mizuho	Neutral
Jun-06-24	Initiated	Goldman	Buy
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Sep-13-23	Initiated	TD Cowen	Market Perform
Jul-10-23	Downgrade	Citigroup	Buy → Neutral
Feb-23-23	Upgrade	Guggenheim	Neutral → Buy
Jan-12-23	Downgrade	Jefferies	Buy → Hold
Sep-30-22	Upgrade	Jefferies	Hold → Buy
Aug-25-22	Initiated	Credit Suisse	Outperform
Aug-04-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-24-22	Initiated	Guggenheim	Neutral
Apr-25-22	Downgrade	Jefferies	Buy → Hold
Apr-07-22	Initiated	Stephens	Overweight
Feb-17-22	Reiterated	BofA Securities	Buy
Feb-17-22	Upgrade	Citigroup	Neutral → Buy
Feb-17-22	Reiterated	Deutsche Bank	Buy
Feb-17-22	Reiterated	Morgan Stanley	Overweight
Feb-17-22	Reiterated	UBS	Buy
Aug-05-21	Resumed	Credit Suisse	Neutral
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Sep-10-20	Upgrade	Jefferies	Hold → Buy
Jul-01-20	Upgrade	BofA Securities	Neutral → Buy
May-13-20	Upgrade	UBS	Neutral → Buy
Apr-21-20	Downgrade	Jefferies	Buy → Hold
Mar-27-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-02-20	Initiated	Deutsche Bank	Buy
Feb-18-20	Upgrade	Wolfe Research	Peer Perform → Outperform
Jan-10-20	Upgrade	Goldman	Neutral → Buy
Jan-08-20	Initiated	Wells Fargo	Overweight
Jan-07-20	Initiated	Citigroup	Buy
Oct-18-19	Downgrade	BofA/Merrill	Buy → Neutral
Jun-10-19	Initiated	SVB Leerink	Outperform
Apr-30-19	Resumed	Evercore ISI	Outperform
Dec-14-18	Initiated	Deutsche Bank	Buy
Oct-09-18	Initiated	UBS	Neutral
Aug-23-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jul-17-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jun-15-18	Upgrade	KeyBanc Capital Mkts	Sector Weight → Overweight
Feb-14-18	Upgrade	SunTrust	Hold → Buy

View All

Charles River Laboratories International Inc Stock (CRL) Latest News

Sep 30, 2026

Charles River Laboratories Stock: Company Reaffirms 2026 Guidance and Sets 2030 Targets - AD HOC NEWS

Sep 30, 2026

Charles River Labs Q3 Results: Adj EPS Expected At $2.90$3.00 - scanx.trade

Sep 30, 2026

UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175 - Moomoo

Sep 30, 2026

Halper Sadeh investigates Charles River Labs over fiduciary breaches - scanx.trade

Sep 30, 2026

Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today - Benzinga

Sep 30, 2026

Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year? - Zacks Investment Research

Sep 30, 2026

UBS resumes Charles River Labs stock coverage with buy rating By Investing.com - Investing.com Australia

Sep 30, 2026

UBS resumes Charles River Labs stock coverage with buy rating - Investing.com

Sep 30, 2026

UBS Initiates Buy on Charles River Laboratories (CRL) Amid Positive CRO Sector Outlook - GuruFocus

Sep 30, 2026

Charles River Laboratories stock pre-market as Cooke & Bieler cites demand stabilization - AD HOC NEWS

Sep 30, 2026

Sep 29, 2026

Return on invested capital % of Charles River Laboratories International, Inc. – HAN:RV6 - TradingView

Sep 29, 2026

Charles River stock: Company reaffirms 2026 guidance and sets 2030 targets - AD HOC NEWS

Sep 29, 2026

Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery - Yahoo Finance

Sep 29, 2026

Charles River Laboratories International, Inc. Cash Flow – HAN:RV6 - TradingView

Sep 29, 2026

Charles River Laboratories stock trades near a yearly high as targets rise - AD HOC NEWS

Sep 29, 2026

Sep 28, 2026

Charles River Laboratories stock at USD 294.59 on September 28, 2026 - AD HOC NEWS

Sep 28, 2026

Sep 27, 2026

Should Long Term Growth Targets Require Action From Charles River Labs Stock Investors? - Simply Wall Street

Sep 27, 2026

Is Charles River Laboratories Stock Outperforming the S&P 500? - Barchart.com

Sep 27, 2026

Sep 26, 2026

Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating - moomoo.com

Sep 26, 2026

Charles River (NYSE:CRL) In Focus As Investor Day Unveils Pathway To Purpose And Lifts Near-Term View - Kalkine Media

Sep 26, 2026

Sep 25, 2026

Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan - Yahoo Finance

Sep 25, 2026

Charles River Labs stock sets USD 11.45 EPS outlook after Investor Day - AD HOC NEWS

Sep 25, 2026

Charles River Laboratories: Positive Investor Day Is Fully Priced In (NYSE:CRL) - Seeking Alpha

Sep 25, 2026

Mizuho raises Charles River Labs stock price target to $295 on outlook - Investing.com

Sep 25, 2026

RBC Raises Price Target on Charles River Laboratories International to $322 From $282, Keeps Outperform Rating - Yahoo Finance

Sep 25, 2026

Evercore ISI Adjusts PT on Charles River Laboratories International to $330 From $320, Maintains Outperform Rating - marketscreener.com

Sep 25, 2026

TD Cowen raises Charles River Labs stock price target on growth outlook - Investing.com Canada

Sep 25, 2026

Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch - Yahoo Finance

Sep 25, 2026

Sep 24, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 24, 2026

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : TD COWEN RAISES TARGET PRICE TO $325 FROM $300 - Bitget

Sep 24, 2026

CRL: 2030 targets: 5%-7% sales CAGR, ~24% margins, $300M savings, and digital-driven growth - TradingView

Sep 24, 2026

CRL: 2030 targets: 5%-7% sales CAGR, 24% margins, and $300M in savings via AI-driven modernization - TradingView

Sep 24, 2026

Charles River Laboratories International Jumps 5.1% in Broad Rally - AlphaStreet

Sep 24, 2026

Charles River Laboratories International Inc Stock (CRL) Moved Up by 7.23% on Sep 24: Facts Behind the Movement - TradingKey

Sep 24, 2026

Charles River Laboratories rises after reaffirming 2026 outlook and unveiling 2030 targets - Quiver Quantitative

Sep 24, 2026

Charles River Laboratories International (CRL) As Faster Cell Banking Fuels A Modest Undervalued View - Simply Wall Street

Sep 24, 2026

Charles River stock rises on promising 2026 outlook (CRL:NYSE) - Seeking Alpha

Sep 24, 2026

Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday - Benzinga

Sep 24, 2026